RNA and nanocarriers: next generation drug and delivery platform take center stage

Jessica Rouge

doi:10.1016/j.tibtech.2022.12.019

RNA and nanocarriers: next generation drug and delivery platform take center stage

Trends Biotechnol. 2023 Mar;41(3):281-282. doi: 10.1016/j.tibtech.2022.12.019. Epub 2023 Jan 4.

Author

Jessica Rouge¹

Affiliation

¹ University of Connecticut, Department of Chemistry, 55 North Eagleville Rd, Storrs, CT 06269, USA. Electronic address: jessica.rouge@uconn.edu.

Abstract

The unprecedented rapid deployment of mRNA vaccines against COVID-19 can be traced back to the early studies of RNA nanocarriers, including the study by Zimmermann et al. which showcased the effectiveness of RNA nanocarriers in vivo. This study, among others, ultimately resulted in Onpattro, the first FDA-approved RNA formulation.

MeSH terms

COVID-19 Vaccines
COVID-19*
Drug Carriers
Humans
Nanoparticles*

Substances

COVID-19 Vaccines
Drug Carriers